A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

This study is for the treatment of metastatic hormone-sensitive prostate cancer.

Study phase: III

Primary disease category: Cancer

Secondary disease categories: Cancer, Prostate Cancer

Sponsor: Southwest Oncology Group

Protocol number: S1216

Projected enrollment dates: July 2013 to July 2020

Official study title: S1216 A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer